Who
Douglas J. Swirsky
Director
Company insider
Files Form 4 as: Director, Cellectar Biosciences; Chief Financial Officer, MaxCyte; Director, MetaVia; Director, Fibrocell Science; President and CEO, Opus Genetics; Director, Pernix Therapeutics Holdings; President and CEO, Genvec; Director, Polymedix.
In numbers
- Trades disclosed
- 87
- Buys
- 10
- Sells
- 2
- Bought
- $236K
- Sold
- $39K
- Companies
- 8
- Companies where not an officer
- 5
- First trade
- 18 Sep 2006
- Last trade
- 7 Jul 2026
- Last filed
- 8 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 7 Jul 2026filed 8 Jul 2026 | CLRB Cellectar Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —37,500 at $0.00 | filing |
| 7 Jul 2026filed 8 Jul 2026 | CLRB Cellectar Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —37,500 at $0.00 | filing |
| 17 Mar 2026filed 19 Mar 2026 | MXCT MaxCyteLife-science tools | SEC FORM 4 Sold | $8,26610,142 at $0.815 | filing |
| 17 Mar 2026filed 19 Mar 2026 | MXCT MaxCyteLife-science tools | SEC FORM 4 Sold | $8,31610,142 at $0.82 | filing |
| 13 Aug 2025filed 13 Aug 2025 | MXCT MaxCyteLife-science tools | SEC FORM 4 Bought | $65K50,000 at $1.29 | filing |
| 18 Mar 2025filed 20 Mar 2025 | MXCT MaxCyteLife-science tools | SEC FORM 4 Sold | $22K6,939 at $3.18 | filing |
| 14 Mar 2025filed 18 Mar 2025 | MXCT MaxCyteoption or derivative · Life-science tools | SEC FORM 4 Code A | —150,000 at $0.00 | filing |
| 14 Mar 2025filed 18 Mar 2025 | MXCT MaxCyteLife-science tools | SEC FORM 4 Code A | —37,500 at $0.00 | filing |
| 14 Feb 2025filed 18 Feb 2025 | CLRB Cellectar Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —90,000 at $0.00 | filing |
| 14 Jun 2024filed 18 Jun 2024 | CLRB Cellectar Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —90,000 at $0.00 | filing |
| 15 Mar 2024filed 19 Mar 2024 | MXCT MaxCyteoption or derivative · Life-science tools | SEC FORM 4 Code A | —225,000 at $0.00 | filing |
| 15 Mar 2024filed 19 Mar 2024 | MXCT MaxCyteLife-science tools | SEC FORM 4 Code A | —81,250 at $0.00 | filing |
| 28 Jun 2023filed 28 Jun 2023 | CLRB Cellectar Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —37,500 at $0.00 | filing |
| 27 Mar 2023filed 28 Mar 2023 | MXCT MaxCyteoption or derivative · Life-science tools | SEC FORM 4 Code A | —350,000 at $0.00 | filing |
| 24 Jun 2022filed 1 Aug 2022 | CLRB Cellectar Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —11,700 at $0.00 | filing |
| 14 Sep 2021filed 14 Sep 2021 | CLRB Cellectar BiosciencesBiotechnology | SEC FORM 4 Bought | $26K25,000 at $1.04 | filing |
| 30 Jun 2021filed 2 Jul 2021 | CLRB Cellectar Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —117,000 at $0.00 | filing |
| 1 Sep 2020filed 3 Sep 2020 | MTVA MetaViaoption or derivative · Biotechnology | SEC FORM 4 Code A | —60,000 at $0.00 | filing |
| 24 Jun 2020filed 25 Jun 2020 | CLRB Cellectar Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —80,000 at $0.00 | filing |
| 13 Dec 2019filed 13 Dec 2019 | Fibrocell Scienceoption or derivative | SEC FORM 4 Code D | —534 | filing |
News
MaxCyte Sees Preliminary Q3 Core Revenue Of About $8.1 Mln, Raises FY26 Guidance; Shares UpMXCT · rttnews.com · 14 Oct 2026MaxCyte Reports Preliminary Third Quarter 2026 Revenue and Raises Full Year 2026 Revenue GuidanceMXCT · manilatimes.net · 14 Oct 2026
0 headlines in the last 90 days name Douglas J. Swirsky; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.